X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761072
https://www.businesswire.com/news/home/20231022057773/en/Celltrion-USA-Announces-U.S.-FDA-Approval-of-ZYMFENTRA%C2%AE-infliximab-dyyb-the-First-and-Only-Subcutaneous-infliximab-for-the-Treatment-of-People-With-Inflammatory-Bowel-Disease
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761358
https://endpts.com/jj-finalizes-25m-settlement-laying-remicade-antitrust-allegations-to-rest/
https://endpts.com/jj-finalizes-25m-settlement-laying-remicade-antitrust-allegations-to-rest/
https://www.pharmafile.com/news/744122/celltrion-submits-application-ct-p13-sc-fda
https://www.sgs.com/en-us/news/2022/07/sgs-s-quay-pharma-collaborates-to-develop-new-oral-medicine-for-inflammatory-bowel-disease
https://www.clinicaltrialsarena.com/news/nih-covid-trial-survival/
https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-drug-fails-meet-main-goal-covid-study-2022-06-02/
https://www.expresspharma.in/immune-modulator-drugs-improves-survival-for-people-hospitalised-with-covid-19/
https://www.centerforbiosimilars.com/view/sc-infliximab-superior-to-iv-dosage-in-patients-with-crohn-s-disease-ulcerative-colitis
https://recalls-rappels.canada.ca/en/alert-recall/quantum-blue-anti-infliximab
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761054
https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-takeda-s-narcolepsy-trial-problem-gene-therapy-pact-human-error
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103772
https://khn.org/news/article/biologic-biosimilar-remicade-inflectra-drug-prices-patient-choice/
https://www.statnews.com/2021/09/21/biosimilar-remicade-biologic-switching/
https://www.reuters.com/business/healthcare-pharmaceuticals/who-led-trial-study-three-anti-inflammatory-drugs-covid-19-patients-2021-08-11/
https://www.fiercepharma.com/pharma/j-j-amgen-and-roche-face-growing-competition-from-biosimilars-are-driving-down-prices-report
https://www.sciencemag.org/news/2021/08/giant-trial-covid-19-treatments-restarting-here-are-drugs-it-s-betting
https://www.prnewswire.com/news-releases/baysient-launches-digital-tdm-app-for-fast-personalized-infliximab-dosing-301321624.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125544
https://www.prnewswire.com/news-releases/children-with-severe-mis-c-do-better-when-treated-initially-with-combined-ivig-and-steroids-301314166.html
https://pink.pharmaintelligence.informa.com/PS144492/NICE-Decision-On-Arthritis-Opens-Door-For-Biosimilars-In-England
https://www.nice.org.uk/news/article/nice-recommends-several-treatment-options-to-help-thousands-with-moderate-rheumatoid-arthritis#:~:text=NICE%20has%20today%20(10th,for%20use%20within%20the%20NHS.
https://www.globenewswire.com/news-release/2021/06/01/2239371/0/en/Biogen-and-Bio-Thera-Announce-Positive-Results-From-Phase-3-Study-of-BAT1806-a-Proposed-Biosimilar-Referencing-Actemra-Tocilizumab.html
https://www.businesswire.com/news/home/20210331005436/en/Celltrion-Healthcare-receives-positive-CHMP-opinion-for-subcutaneous-formulation-of-infliximab-Remsima%C2%AE-SC-for-direct-use-of-subcutaneous-therapy-without-IV-loading-in-adults-with-rheumatoid-arthritis
https://www.grifols.com/en/view-news/-/news/grifols-launches-patient-point-of-care-system-for-monitoring-infliximab-in-europe#:~:text=Barcelona%2C%20Spain%2C%20March%2018%2C,%2Dcare%20(POC)%20system%20for
https://www.medindia.net/health-press-release/Egis-Pharmaceuticals-PLC-Announces-Regi[%E2%80%A6]ecision-Medicine-Tool-for-Therapy-Selection-in--516488-1.htm
https://int.egis.health/cps/egis-pharmaceuticals-plc-announces-registration-of-the-first-blood-based-ce-ivd-precision-medicine-t
https://www.bigmoleculewatch.com/2021/03/02/meta-analysis-finds-nonsignificant-differences-between-infliximab-biosimilars/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+GoodwinProcter-BigMoleculeWatchBlog+%28Big+Molecule+Watch+Blog+%7C+Goodwin%29
https://www.globenewswire.com/news-release/2020/10/26/2114254/0/en/Samsung-Bioepis-Announces-First-Real-World-Data-on-RENFLEXIS-infliximab-abda-with-IBD-patients-from-Veterans-Affairs-Healthcare-System-at-the-American-College-of-Gastroenterology-A.html
https://endpts.com/icer-criticizes-cost-of-8-targeted-immune-modulators-for-uc-recommending-some-deep-discounts/
http://www.pharmafile.com/news/554588/celltrions-infliximab-biosimilar-remsima-secures-european-approval-five-indications
https://www.biospace.com/article/releases/european-commission-grants-marketing-authorisation-for-world-s-first-subcutaneous-formulation-of-infliximab-remsima-sc-for-an-additional-five-indications-including-for-use-in-inflammatory-bowel-disease-and-ankylosing-spondylitis-/
https://health.economictimes.indiatimes.com/news/pharma/anti-inflammatory-and-cancer-drugs-tested-in-uk-as-possible-covid-19-therapy/76303703
https://www.clinicaltrialsarena.com/news/catalyst-trial-first-two-candidates/
https://hemophilianewstoday.com/2020/05/28/covid-19-delaying-rare-disease-gene-therapy-trials-pharma-execs-say/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103772
Market Place
Share 
